|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This pilot study highlights the relevance of secreted miR-210-3p as powerful non-invasive prognostic and predictive biomarker for the evaluation of clinical outcomes and treatment response during ccRCC follow up.
|
31771042 |
2020 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, Serum exosomal miR-210 originating from tumor tissue has potential as a novel noninvasive biomarker for the detection and prognosis of ccRCC.
|
30304555 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified and validated multiple miRNAs dysregulated in ccRCC tissues; miR-155-5p and miR-210-3p were predictive of ccRCC recurrence, pointing to potential utility as biomarkers and underlying biological mechanisms.
|
30201497 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A total of 7 publicly available and independent RCC miRNA expression profiling datasets were collected, and 2 upregulated (hsa-miR-155-5p and hsa-miR-210-5p) and 6 downregulated (hsa-miR-138-5p, hsa-miR-141-5p, hsa-miR-200c-5p, hsa-miR-362-5p, hsa-miR-363-5p and hsa-miR-429) meta-signature miRNAs in renal carcinoma were identified.
|
30344735 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.
|
29445446 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Secreted miR-210-3p as non-invasive biomarker in clear cell renal cell carcinoma.
|
29050224 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Patients with higher levels of miR-210, miR-221 and miR-1233 presented a higher risk of specific death by RCC and a lower cancer-specific survival.
|
29262564 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, a new nanopore-based detection scheme utilizing a borosilicate micropipette and an assay of complementary γ-peptide nucleic acid (γ-PNA) probes conjugated to polystyrene beads have been reported for the detection of miR-204 and miR-210 related to the clear cell Renal Cell Carcinoma (ccRCC).
|
28832110 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that renal cell carcinoma progression is promoted by TWIST1 suppression mediated by miR-210-3p.
|
28152509 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The level of urinary cell-free miR-210 was significantly higher in patients with ccRCC than in control subjects (P<0.001).
|
28089386 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To this end we selected four miRNAs (miR-21-5p, miR-210-3p, miR-185-5p and miR-221-3p) and their expression has been evaluated in a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissues from 20 ccRCC patients who underwent surgical nephrectomy resection. miR-21-5p and miR-210-3p resulted the most significantly up-regulated miRNAs in this patient cohort, highlighting these onco-miRNAs as possible relevant players involved in ccRCC tumorigenesis.
|
26670229 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a cohort of 45 patients, the high expression of miR-21 (HR: 5.46, 95%CI: 2.02-53.39) and miR-210 (HR: 6.85, 95%CI: 2.13-43.36), the low expression of miR-141 (HR: 0.16, 95%CI: 0.004-0.18), miR-200c (HR: 0.08, 95%CI: 0.01-0.43) and miR-429 (HR: 0.18, 95%CI: 0.02-0.50) were associated with poor cancer-specific survival (CSS) following RCC resection.
|
25974855 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of predicted targets that might be involved in carcinogenesis and aggressive tumor behavior were identified. miR-210 is a potential therapeutic target and independent marker of poor prognosis of ccRCC.
|
25555365 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.
|
26426010 |
2015 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, many studies using miRNA microarray analysis demonstrated that miR-210 expression in clear cell carcinoma (CCC), which is the largest subtype of RCC, was significantly upregulated in tumor tissue.
|
24212760 |
2014 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased expression levels of miR-210 in RCC tumor tissue were independently validated.
|
23150176 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma.
|
23064048 |
2013 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to confirming that canonical cancer genes and miRNAs (including VEGFA, DUSP9 and ERBB4; miR-210, miR-184 and miR-206) play pivotal roles in ccRCC development, promising novel candidates (such as PNCK and miR-122) without previous annotation in ccRCC carcinogenesis were also discovered in this study.
|
21253009 |
2010 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Five miRNAs highly upregulated in RCC4 + VHL and five miRNAs highly downregulated in RCC4 + VHL were studied further, in addition to miR-210, which is regulated by the HIF-VHL system. miRNA expression was also measured in 31 cc RCC tumours compared to adjacent normal tissue.
|
20964835 |
2010 |